Fetal Cells in Maternal Blood: A Six-Fold Increase in Women who have Undergone Amniocentesis and Carry a Fetus with Down Syndrome: A Multicenter Study

Abstract

Fetal nucleated red blood cells (FNRBCs) circulate in the maternal blood throughout pregnancy. Even if the frequency of fetal cells in the maternal circulation remains to be ascertained, complications of pregnancy such as fetal cells aneuploidies, preeclampsia, abnormal Doppler of the uterine artery without symptoms of preeclampsia, fetal growth restriction and polyhydramnios are associated with an increased feto-maternal trafficking. Based on these observations, previous studies have suggested that determination of the fetal nucleated red blood cell count (FNRBCC) might be a useful non-invasive screening test, either alone or in combination with existing maternal tests, for the non-invasive assessment of aneuploidies, in particular Down syndrome (DS). In this paper we have evaluated the distribution of FNRBCC in a set of 18 normal pregnancies and 18 pregnancies with a trisomy 21-affected fetus, matching for gestational age, maternal age, and, when possible, fetal gender, in order to quantify the difference in the number of fetal cells between the two populations. Maternal blood was collected from each pregnant woman two to three weeks after amniocentesis after knowing the cytogenetic results. Correlation of FNRBCC with the gestational week and clinical status (affected vs. non affected) by multiple regression analysis provided significant results (p < 0.001). Adjusted values of FNRBCC were 48 ± 10.2 in controls and 301 ± 17.01 in DS cases, corresponding to a 6.27fold increase. These retrospective results prompt a prospective evaluation of the use of FNRBCC for screening purposes.

Fetal nucleated red blood cells - fetal nucleated red blood cells count (FNRBCC) - Down syndrome - general linear model - screening method

References

• 1 Al-Mufti R, Hambley H, Farzaneh F, Nicolaides K. Investigation of maternal blood enriched for fetal cells: role in screening and diagnosis of fetal trisomies.  Am J Med Genet. 1999;  85 66-75
• 2 Bianchi D W, Williams J M, Sullivan L M, Hanson F W, Klinger K W, Shuber A P. PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies.  Am J Hum Genet. 1997;  61 822-829
• 3 Bianchi D W, Simpson J L, Jackson L G, Elias S, Holzgreve W, Evans M I, Dukes K A. et al . Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study.  Prenat Diagn. 2002;  22 609-615
• 4 Cha D, Hogan B, Bohmer R M, Bianchi D W, Johnson K L. A simple and sensitive erythroblast scoring system to identify fetal cells in maternal blood.  Prenat Diagn. 2003;  23 68-73
• 5 Farina A, Bianchi D W. Fetal cells in maternal blood as a second non-invasive step for fetal Down syndrome screening.  Prenat Diagn. 1998;  18 983-984
• 6 Merchant F A, Castelman K R. Strategies for automated fetal cell screening.  Hum Reprod Update. 2002;  8 509-521
• 7 Parano E, Falcidia E, Grillo A, Takabayashi H, Trifiletti R R, Pavone P. Fetal nucleated red blood cell counts in peripheral blood of mothers bearing Down syndrome fetus.  Neuropediatrics. 2001;  32 147-149
• 8 Pertl B, Bianchi D W. First trimester prenatal diagnosis: fetal cells in the maternal circulation.  Semin Perinatol. 1999;  23 393-402
• 9 Snijders R J, Noble P, Sebire N, Souka A, Nicolaides K H. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10 - 14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.  Lancet. 1998;  1 343-346
• 10 Wald N J, Densem J W, Smith D, Klee G G. Four-marker serum screening for Down's syndrome.  Prenat Diagn. 1994;  14 707-716

1 These authors contributed equally to the manuscript.